Back to Search
Start Over
Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
- Source :
-
Expert review of neurotherapeutics [Expert Rev Neurother] 2024 Jun; Vol. 24 (6), pp. 549-553. Date of Electronic Publication: 2024 May 17. - Publication Year :
- 2024
-
Abstract
- Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive motor neuron disorder with a fatal outcome 3-5 years after disease onset due to respiratory complications. Superoxide dismutase 1 (SOD1) mutations are found in about 2% of all patients. Tofersen is a novel oligonucleotide antisense drug specifically developed to treat SOD1-ALS patients.<br />Areas Covered: Our review covers and discusses tofersen pharmacological properties and its phase I/II and III clinical trials results. Other available drugs and their limitations are also addressed.<br />Expert Opinion: VALOR study failed to meet the primary endpoint (change in the revised Amyotrophic Lateral Sclerosis Functional Rating Scale score from baseline to week 28, tofersen arm vs. placebo), but a significant reduction in plasma neurofilament light chain (NfL) levels was observed in tofersen arm (60% vs. 20%). PrefALS study has proposed plasma NfL has a potential biomarker for presymptomatic treatment, since it increases 6-12 months before phenoconversion. There is probably a delay between plasma NfL reduction and the clinical benefit. ATLAS study will allow more insights regarding tofersen clinical efficacy in disease progression rate, survival, and even disease onset delay in presymptomatic SOD1 carriers.
Details
- Language :
- English
- ISSN :
- 1744-8360
- Volume :
- 24
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Expert review of neurotherapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 38758193
- Full Text :
- https://doi.org/10.1080/14737175.2024.2355983